Literature DB >> 24780758

Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.

Eva Schlecker1, Nathalie Fiegler1, Annette Arnold1, Peter Altevogt2, Stefan Rose-John3, Gerhard Moldenhauer2, Antje Sucker4, Annette Paschen4, Elke Pogge von Strandmann5, Sonja Textor6, Adelheid Cerwenka1.   

Abstract

Natural killer (NK) cells are potent immune effector cells capable of mediating antitumor responses. Thus, during immunoediting, tumor cell populations evolve strategies to escape NK-cell-mediated recognition. In this study, we report a novel mechanism of immune escape involving tumor cell shedding of B7-H6, a ligand for the activating receptor NKp30 that mediates NK-cell binding and NK-cell-mediated killing. Tumor cells from different cancer entities released B7-H6 by ectodomain shedding mediated by the cell surface proteases "a disintegrin and metalloproteases" (ADAM)-10 and ADAM-17, as demonstrated through the use of pharmacologic inhibitors or siRNA-mediated gene attenuation. Inhibiting this proteolytic shedding process increased the levels of B7-H6 expressed on the surface of tumor cells, enhancing NKp30-mediated activation of NK cells. Notably, we documented elevated levels of soluble B7-H6 levels in blood sera obtained from a subset of patients with malignant melanoma, compared with healthy control individuals, along with evidence of elevated B7-H6 expression in melanoma specimens in situ. Taken together, our results illustrated a novel mechanism of immune escape in which tumor cells impede NK-mediated recognition by metalloprotease-mediated shedding of B7-H6. One implication of our findings is that therapeutic inhibition of specific metalloproteases may help support NK-cell-based cancer therapy. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24780758     DOI: 10.1158/0008-5472.CAN-13-3017

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  79 in total

1.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.

Authors:  Guoshuai Cao; Jian Wang; Xiaodong Zheng; Haiming Wei; Zhigang Tian; Rui Sun
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

2.  NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells.

Authors:  Elke Pogge von Strandmann; Olga Shatnyeva; Hinrich P Hansen
Journal:  Ann Transl Med       Date:  2015-11

Review 3.  The B7 Family Member B7-H6: a New Bane of Tumor.

Authors:  Ying Chen; Jun Mo; Xi Jia; Yang He
Journal:  Pathol Oncol Res       Date:  2017-10-31       Impact factor: 3.201

4.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

5.  Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer.

Authors:  Jing Sun; Hong Tao; Xiaoning Li; Lu Wang; Jie Yang; Pingping Wu; Yaqin Zhang; Yundi Guo
Journal:  Oncol Lett       Date:  2017-06-19       Impact factor: 2.967

6.  B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape.

Authors:  Silvia Pesce; Giovanna Tabellini; Claudia Cantoni; Ornella Patrizi; Daniela Coltrini; Fabio Rampinelli; Jessica Matta; Eric Vivier; Alessandro Moretta; Silvia Parolini; Emanuela Marcenaro
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

Review 7.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

8.  Enhanced activation of human NK cells by drug-exposed hepatocytes.

Authors:  Frank Fasbender; Martin Obholzer; Sarah Metzler; Regina Stöber; Jan G Hengstler; Carsten Watzl
Journal:  Arch Toxicol       Date:  2020-02-14       Impact factor: 5.153

9.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

10.  The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.

Authors:  Sonja Textor; Felicitas Bossler; Kai-Oliver Henrich; Moritz Gartlgruber; Julia Pollmann; Nathalie Fiegler; Annette Arnold; Frank Westermann; Nina Waldburger; Kai Breuhahn; Sven Golfier; Mathias Witzens-Harig; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-07-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.